Endocrine Gland Neoplasms  >>  CP-870893  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CP-870893 / Pfizer
NCT00711191: A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas

Checkmark In combination with gemcitabine in pts with adv pancreatic ductal adenocarcinoma
Aug 2013 - Aug 2013: In combination with gemcitabine in pts with adv pancreatic ductal adenocarcinoma
Completed
1
22
US
monoclonal antibody, chemotherapy
Hoffmann-La Roche, University of Pennsylvania
Pancreatic Neoplasm
01/11
01/11
NCT01456585: Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma

Completed
1
10
US
Gemcitabine, CP-870,893
Abramson Cancer Center of the University of Pennsylvania
Adenocarcinoma Pancreas
04/13
04/13

Download Options